The European Medicines Agency is surveying drugmakers in the United Kingdom on their preparedness for the UK’s exit from the European Union.
The survey aims to identify which drugmakers are most likely to need assistance during the transition and help the EMA and European Commission allocate resources. More than a third of centrally authorized products on the EU are manufactured by companies in the UK.
The agency has already begun distributing the survey to drugmakers in the UK and those with key portions of their operations in the UK. The deadline for completion is Feb. 9.